Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations

This publication has 43 references indexed in Scilit:

• Epidermal growth factor receptor (EGFR) signaling in cancer
  Gene, 2005
• Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
  JNCI Journal of the National Cancer Institute, 2005
• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
  New England Journal of Medicine, 2005
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
  Published by Elsevier ,2005
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLoS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody
  Journal of Cellular Physiology, 1990
• Signal Transduction Through the EGF Receptor Transfected in IL-3-Dependent Hematopoietic Cells
  Science, 1988